Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size, Status and Forecast 2021-2027

Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size, Status and Forecast 2021-2027

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Oral Medications
1.2.3 Temozolomide
1.2.4 Radiosensitizers
1.2.5 Nitrosoureas Drugs
1.2.6 Radiation Therapy
1.2.7 Chemotherapy
1.3 Market by Application
1.3.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Perspective (2016-2027)
2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Growth Trends by Regions
2.2.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Industry Dynamic
2.3.1 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Trends
2.3.2 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Drivers
2.3.3 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Challenges
2.3.4 Recurrent Glioblastoma Multiforme (GBM) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Revenue
3.1.1 Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Revenue (2016-2021)
3.1.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue
3.4 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio
3.4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue in 2020
3.5 Recurrent Glioblastoma Multiforme (GBM) Treatment Key Players Head office and Area Served
3.6 Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Product Solution and Service
3.7 Date of Enter into Recurrent Glioblastoma Multiforme (GBM) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Recurrent Glioblastoma Multiforme (GBM) Treatment Breakdown Data by Type
4.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Type (2022-2027)
5 Recurrent Glioblastoma Multiforme (GBM) Treatment Breakdown Data by Application
5.1 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2016-2027)
6.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
6.2.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021)
6.2.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027)
6.2.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2027)
6.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application
6.3.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021)
6.3.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027)
6.3.3 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2027)
6.4 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country
6.4.1 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021)
6.4.2 North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2016-2027)
7.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
7.2.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2027)
7.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application
7.3.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2027)
7.4 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country
7.4.1 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
8.2.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application
8.3.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region
8.4.1 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2016-2027)
9.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
9.2.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2027)
9.3 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application
9.3.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2027)
9.4 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country
9.4.1 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type
10.2.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application
10.3.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country
10.4.1 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Astrazeneca
11.1.1 Astrazeneca Company Details
11.1.2 Astrazeneca Business Overview
11.1.3 Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.1.4 Astrazeneca Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
11.1.5 Astrazeneca Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.2.4 Roche Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
11.2.5 Roche Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Details
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.3.4 GlaxoSmithKline Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
11.3.5 GlaxoSmithKline Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.4.4 Merck Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
11.4.5 Merck Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.5.4 Pfizer Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
11.5.5 Pfizer Recent Development
11.6 AngioChem
11.6.1 AngioChem Company Details
11.6.2 AngioChem Business Overview
11.6.3 AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.6.4 AngioChem Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
11.6.5 AngioChem Recent Development
11.7 Vascular Biogeneics
11.7.1 Vascular Biogeneics Company Details
11.7.2 Vascular Biogeneics Business Overview
11.7.3 Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Introduction
11.7.4 Vascular Biogeneics Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
11.7.5 Vascular Biogeneics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Oral Medications
Table 3. Key Players of Temozolomide
Table 4. Key Players of Radiosensitizers
Table 5. Key Players of Nitrosoureas Drugs
Table 6. Key Players of Radiation Therapy
Table 7. Key Players of Chemotherapy
Table 8. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2016-2021)
Table 12. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2022-2027)
Table 14. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Trends
Table 15. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Drivers
Table 16. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Challenges
Table 17. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Restraints
Table 18. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Players (2016-2021)
Table 20. Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment as of 2020)
Table 21. Ranking of Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Recurrent Glioblastoma Multiforme (GBM) Treatment Product Solution and Service
Table 25. Date of Enter into Recurrent Glioblastoma Multiforme (GBM) Treatment Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2016-2021)
Table 29. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Application (2016-2021)
Table 33. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 65. Astrazeneca Company Details
Table 66. Astrazeneca Business Overview
Table 67. Astrazeneca Recurrent Glioblastoma Multiforme (GBM) Treatment Product
Table 68. Astrazeneca Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million)
Table 69. Astrazeneca Recent Development
Table 70. Roche Company Details
Table 71. Roche Business Overview
Table 72. Roche Recurrent Glioblastoma Multiforme (GBM) Treatment Product
Table 73. Roche Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million)
Table 74. Roche Recent Development
Table 75. GlaxoSmithKline Company Details
Table 76. GlaxoSmithKline Business Overview
Table 77. GlaxoSmithKline Recurrent Glioblastoma Multiforme (GBM) Treatment Product
Table 78. GlaxoSmithKline Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million)
Table 79. GlaxoSmithKline Recent Development
Table 80. Merck Company Details
Table 81. Merck Business Overview
Table 82. Merck Recurrent Glioblastoma Multiforme (GBM) Treatment Product
Table 83. Merck Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million)
Table 84. Merck Recent Development
Table 85. Pfizer Company Details
Table 86. Pfizer Business Overview
Table 87. Pfizer Recurrent Glioblastoma Multiforme (GBM) Treatment Product
Table 88. Pfizer Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million)
Table 89. Pfizer Recent Development
Table 90. AngioChem Company Details
Table 91. AngioChem Business Overview
Table 92. AngioChem Recurrent Glioblastoma Multiforme (GBM) Treatment Product
Table 93. AngioChem Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million)
Table 94. AngioChem Recent Development
Table 95. Vascular Biogeneics Company Details
Table 96. Vascular Biogeneics Business Overview
Table 97. Vascular Biogeneics Recurrent Glioblastoma Multiforme (GBM) Treatment Product
Table 98. Vascular Biogeneics Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021) & (US$ Million)
Table 99. Vascular Biogeneics Recent Development
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Oral Medications Features
Figure 3. Temozolomide Features
Figure 4. Radiosensitizers Features
Figure 5. Nitrosoureas Drugs Features
Figure 6. Radiation Therapy Features
Figure 7. Chemotherapy Features
Figure 8. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application: 2020 VS 2027
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Ambulatory Surgical Centers Case Studies
Figure 12. Recurrent Glioblastoma Multiforme (GBM) Treatment Report Years Considered
Figure 13. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions: 2020 VS 2027
Figure 16. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Regions (2022-2027)
Figure 17. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Players in 2020
Figure 18. Global Top Recurrent Glioblastoma Multiforme (GBM) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recurrent Glioblastoma Multiforme (GBM) Treatment as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue in 2020
Figure 20. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2016-2021)
Figure 21. Global Recurrent Glioblastoma Multiforme (GBM) Treatment Revenue Market Share by Type (2022-2027)
Figure 22. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2016-2027)
Figure 24. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2016-2027)
Figure 25. North America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Country (2016-2027)
Figure 26. United States Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2016-2027)
Figure 30. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2016-2027)
Figure 31. Europe Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Country (2016-2027)
Figure 32. Germany Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Region (2016-2027)
Figure 42. China Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2016-2027)
Figure 50. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2016-2027)
Figure 51. Latin America Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Country (2016-2027)
Figure 52. Mexico Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Recurrent Glioblastoma Multiforme (GBM) Treatment Market Share by Country (2016-2027)
Figure 58. Turkey Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Astrazeneca Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
Figure 62. Roche Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
Figure 63. GlaxoSmithKline Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
Figure 64. Merck Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
Figure 65. Pfizer Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
Figure 66. AngioChem Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
Figure 67. Vascular Biogeneics Revenue Growth Rate in Recurrent Glioblastoma Multiforme (GBM) Treatment Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029

Published: 11-Jan-2024        Price: US 3350 Onwards        Pages: 118

The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029. Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029. Report Scope This report aims to provide a comprehensive presentation of the glo......

Global Non-imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95

The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 90

The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......

Global PCR Equipment Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 77

The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030. PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers: Advancements in Research and Diagnost......

Global Disposable Sterile Syringes and Needles Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 109

The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030. North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Disposable Sterile Syringes and N......

Global Orthopaedic Power Tools Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030. North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......

Global Cerebrospinal Fluid Management Devices Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......

Global CAD & CAM Milling Burs Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79

The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......

Global Artificial Teeth Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 98

The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs